Table 3. ADR in patients treated for ovarian cancer, stratified by dose level.
| ADR | 220 mg/m2 | 260 mg/m2 | 300 mg/m2 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total | |
| Anemia | 0 (0.0) | 1 (16.7) | 1 (16.7) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 2 (33.3) | 1 (16.7) | 0 (0.0) | 3 (50.0) | 0 (0.0) | 2 (33.3) | 1 (16.7) | 0 (0.0) | 3 (50.0) |
| Neutropenia | 0 (0.0) | 1 (16.7) | 1 (16.7) | 2 (33.3) | 4 (66.7) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 4 (66.7) | 6 (100.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 3 (50.0) | 6 (100.0) |
| Febrile neutropenia | 1 (16.7) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (16.7) |
| Thrombocytopenia | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (16.7) | 1 (16.7) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neuropathy peripheral | 1 (16.7) | 3 (50.0) | 0 (0.0) | 0 (0.0) | 4 (66.7) | 1 (16.7) | 4 (66.7) | 0 (0.0) | 0 (0.0) | 5 (83.3) | 4 (66.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (66.7) |
| Hypersensitivity | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) |
| Urticaria | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 1 (16.7) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) |
| Anorexia | 1 (16.7) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) |
| Nausea | 4 (66.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (66.7) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 3 (50.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 4 (66.7) |
| Vomiting | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) |
| Dizziness | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Abdominal pain | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 1 (16.7) | 1 (16.7) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Constipation | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) |
| Alopecia | 4 (66.7) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 5 (83.3) | 1 (16.7) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 5 (83.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (83.3) |
Values are presented as number (%); Some patients had multiple cases of the indicated condition.
ADR, adverse drug reactions.